Pharmaceutical development of (investigational) anticancer agents for parenteral use - A review

Drug Development and Industrial Pharmacy

Volumn 22, Issue 6, 1996, Pages 475-494

  Jonkman de Vries, J D ^a   Flora, K P ^b   Bult, A ^c   Beijnen, J H ^a,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMSACRINE; ANTINEOPLASTIC AGENT; BRYOSTATIN 1; BUSULFAN; CARZELESIN; CREMOPHOR; CYCLODEXTRIN; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; ETOPOSIDE; FLUOROURACIL; LIPID EMULSION; LIPOPROTEIN; LIPOSOME; N,N DIMETHYLACETAMIDE; PACLITAXEL; PHOTOSENSITIZING AGENT; PRODRUG; PROPYLENE GLYCOL; RACHELMYCIN; SOLVENT; SURFACTANT; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; CANCER INHIBITION; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; COLLOID; CONVULSION; DISORIENTATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FREEZE DRYING; HALLUCINATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; MOUSE; NONHUMAN; PARENTERAL DRUG ADMINISTRATION; PHARMACEUTICS; PHASE 1 CLINICAL TRIAL; QUALITY CONTROL; REVIEW; SIDE EFFECT;

EID: 0029892508     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.3109/03639049609108353     Document Type: Review

References (156)

1. G. Rowlinson-Busza and A. A. Epenetos, Curr. Opinion Oncol., 4, 1142 (1992).
2. G. Schwartsmann, B. Winograd, and H. M. Pinedo, Radiother. Oncol., 12, 301 (1988).
3. J. H. Beijnen, Pharm. Weekblad Sci. Ed., 14, 258 (1992).
4. H. M. Pinedo, Med. Oncol. Tumor Pharmacother., 3, 63 (1986).
5. H. M. Deutsch, J. A. Glinski, M. Hernandez, R. D. Haugwitz, V. L. Narayanan, M. Suffness, and L. H. Zalkow, J. Med. Chem., 32, 788 (1989).
6. R. J. Prankerd, S. G. Frank, and V. J. Stella, J. Parenter. Sci. Technol., 42, 76 (1988).
7. C. B. Hendricks, L. B. Grochow, E. K. Rowinsky, A. A. Forastiere, W. P. McGuire, D. S. Ettinger, S. Sartorius, B. Lubejko, and R. C. Donehower, Cancer Res., 51, 5781 (1991).
8. E. A. Oostveen and W. N. Speckamp, Tetrahedron, 43, 255 (1987).
9. J. H. Smith, M. A. Smith, C. L. Litterst, M. P. Copley, J. Uozumi, and M. R. Boyd, Fundam. Appl. Toxicol., 10, 45 (1988).
10. J. G. Wall, H. A. Burns III, D. D. Von Hoff, G. Rodriguez, R. Kneuper-Hall, D. Shaffer, T. O'Rourke, T. Brown, G. Weiss, G. Clark, S. McVea, J. Brown, R. Johnson, C. Friedman, B. Smith, W. S. Mann, and J. Kuhn, Anti-Cancer Drugs, 3, 337 (1992).
11. C. Y. Paul, J. O. Liliemark, R. H. Farmen, C. R. Franks, M. Uytdenhoef, and C. O. Peterson, Ther. Drug Monit., 9, 263 (1987).
12. M. Gibson, A. J. Denham, P. M. Taylor, and N. I. Payne, J. Parenter. Sci. Technol., 44, 306 (1990).
13. J. M. Cook, A. T. Florence, J. Russell, and T. E. Wheldon, Eur. J. Cancer Clin. Oncol., 25, 311 (1989).
14. J. P. Davignon and J. C. Cradock, Pharm. Weekbl., 119, 1144 (1984).
15. R. S. Knowles and J. E. Virden, Br. J. Med., 281, 589 (1980).
16. M. J. Akers, Am. J. Hosp. Pharm., 44, 2528 (1987).
17. T. Chen, J. M. Lausier, and C. T. Rhodes, Drug Dev. Ind. Pharm., 12, 1041 (1986).
18. J. H. Beijnen, K. P. Flora, G. W. Halbert, R. E. C. Henrar, and J. A. Slack, Br. J. Cancer, 72, 210 (1995).
19. Anonymous, Pharmeuropa, 2, 142 (1990).
20. J. P. Davignon, J. A. Slack, J. H. Beijnen, W. R. Vezin, and T. J. Schoemaker, Eur. J. Cancer Clin. Oncol., 24, 1535 (1988).
21. T. J. Macek, Am. J. Pharm. Sci. Suppl. Public Health, 137, 217 (1965).
22. T. J. Macek, Am. J. Pharm. Sci. Suppl. Public Health, 138, 22 (1966).
23. A. T. Florence, in Techniques of Solubilization of Drugs (S. H. Yalkowsky, ed.), Marcel Dekker, New York, 1981, p. 15.
24. L. A. Trissel, Handbook on Injectable Drugs, 7th ed., American Society of Hospital Pharmacists, Bethesda, 1992, p. 365.
25. L. A. Trissel, Handbook on Injectable Drugs, 7th ed., American Society of Hospital Pharmacists, Bethesda, 1992, p. 971.
26. H. L. McLeod, D. K. Baker Jr, C. H. Pui, and J. H. Rodman, Cancer Chemother. Pharmacol., 29, 150 (1991).
27. W. N. Waugh, L. A. Trissel, and V. J. Stella, Am. J. Hosp. Pharm., 48, 1520 (1991).
28. W. Lorenz, H. J. Riemann, and A. Schmal, Agents Actions, 7, 63 (1977).
29. J. H. Gaudy, J. F. Sicard, F. Lhoste, and J. F. Boitier, Can. J. Anaesth., 34, 122 (1987).
30. R. B. Weiss, R. C. Donehower, P. H. Wiernik, T. Ohnuma, R. J. Gralla, D. L. Trump, J. R. Baker, D. A. VanEcho, D. D. Von Hoff, and B. Leyland-Jones, J. Clin. Oncol., 8, 1263 (1990).
31. P. H. Wiernik, E. L. Schwartz, A. Einzig, J. J. Strauman, R. B. Lipton, and J. P. Dutcher, J. Clin. Oncol., 5, 1232 (1987).
32. E. A. Eisenhauer, W. W. ten Bokkel-Huinink, and K. D. Swenerton, J. Clin. Oncol., 12, 2654 (1994).
33. R. T. Dorr, Ann. Pharmacother., 28, S11 (1994).
34. L. Webster, M. Linsenmeyer, M. Millward, C. Morton, J. Bishop, and D. Woodcock, J. Natl. Cancer Inst., 85, 1685 (1993).
35. M. J. Millward, L. K. Webster, D. Rischin, C. A. Tinnelly, G. C. Toner, J. F. Bishop, M. E. Linsenmeyer, and D. M. Woodcock, Ann. Oncol., 5, 159 (1994).
36. D. S. Chervinsky, M. L. Brecher, R. M. Baker, M. J. Hoelcle, and C. K. Tebbi, Cancer Biother., 8, 67 (1993).
37. J. D. Jonkman-de Vries, M. J. A. De Graaff-Teulen, R. E. C. Henrar, J. J. Kettenes-van den Bosch, A. Bult, and J. H. Beijnen, Invest. New Drugs, 12, 303 (1994).
38. G. F. Fleming, M. J. Ratain, S. M. O'Brien, R. L. Schilsky, P. C. Huffman, J. M. Richards, N. J. Vogelzang, D. A. Kasunic, and R. H. Earhart, J. Natl. Cancer Inst., 86, 368 (1994).
39. D. Lednicer, K. P. Flora, R. Vishnuvajjala, and G. Turner, Ann. Oncol., 5, 168 (1994).
40. S. H. Yalkowsky and T. J. Roseman, in Techniques of Solubilization of Drugs (S. H. Yalkowsky, ed.), Marcel Dekker, New York, 1981, p. 91.
41. J. H. Beijnen, A. U. Beijnen-Bandhoe, A. C. Dubbelman, R. Van Gijn, and W. J. M. Underberg, J. Parenter. Sci. Technol., 45, 108 (1991).
42. R. W. Pfeifer, K. N. Hale, S. E. Cronquist, and M. Daniels, Am. J. Hosp. Pharm., 50, 2518 (1993).
43. H. Bhagwatwar, D. S. Chow, and B. S. Andersson, Proc. Am. Assoc. Cancer Res., 34, 269 (1993).
44. K. K. Chan, A. R. Barrientos, Y. L. Tsai, and A. Srigritsanapol, Proc. Am. Assoc. Cancer Res., 34, 383 (1993).
45. H. O. Alpar, S. J. Whitmarsh, H. Ismail, W. J. Irwin, J. A. Slack, K. A. Belaid, and M. F. G. Stevens, Drug Dev. Ind. Pharm., 12, 1795 (1986).
46. L. A. Trissel, Handbook on Injectable Drugs, 7th ed., American Society of Hospital Pharmacists, Bethesda, 1992, p. 958.
47. A. J. Weiss, L. G. Jackson, R. A. Carabasi, E. L. Mancall, and J. C. White, Cancer Chemother. Rep., 16, 477 (1963).
48. L. A. Al-Razzak and V. J. Stella, Int. J. Pharm., 60, 53 (1990).
49. H. Demey, R. Daelemans, M. E. De Broe, and L. Bossaert, Lancet, 1(8390), 1360 (1984).
50. L. A. Trissel, Handbook on Injectable Drugs, 7th ed., American Society of Hospital Pharmacists, Bethesda, 1992, p.966.
51. K. P. Flora, V. J. Stella, W. N. Waugh, C. Friszman, J. Wilson, B. Vishnuvajjala, and T. Smith, Proc. Am. Assoc. Cancer Res., 34, 365 (1993).
52. M. Rowland and T. N. Tozer, Clinical Pharmacokinetics: Concepts and Applications, 2nd ed., Lea and Febiger, Philadelphia, 1989, p. 385.
53. J. B. Cannon, J. Pharm. Sci., 82, 435 (1993).
54. R. Tenhunen, O. Tokola, and I. B. Linden, J. Pharm. Pharmacol., 39, 780 (1987).
55. L. Volin, T. Ruutu, S. Knuutila, and R. Tenhunen, Leukemia Res., 12, 423 (1988).
56. A. J. Repta, in Techniques of Solubilization of Drugs (S. H. Yalkowsky, ed.), Marcel Dekker, New York, 1981, p. 135.
57. T. Loftsson and H. Fridriksdottir, J. Pharm. Sci., 81, 197 (1992).
58. M. Arellano, L. Lamaire, M. C. Malet-Martino, and R. Martino, EORTC Winter Meeting of the PAMM Group, Toulouse, January 12-14, 1995.
59. O. Bekers, E. V. Uijtendaal, J. H. Beijnen, A. Bult, and W. J. M. Underberg, Drug Dev. Ind. Pharm., 17, 1503 (1991).
60. K. Uekama and M. Otagiri, CRC Crit. Rev. Ther. Drug Carrier Syst., 3, 1 (1987).
61. M. E. Brewster, J. W. Simpkins. M. S. Hora, W. C. Stern, and N. Bodor, J. Parenter. Sci. Technol., 43, 231 (1989).
62. O. Bekers, J. H. Beijnen, B. J. Vis, A. Suenaga, M. Otagiri, A. Bult, and W. J. M. Underberg, Int. J. Pharm., 72, 123 (1991).
63. H. S. Choi, A. M. Knevel, and C. Chang, Pharm. Res., 9, 690 (1992).
64. W. Distelmans, R. Van Ginckel, W. Vanherck, R. Willebrords, L. Wouters, M. De Brabander, and J. Mesens, Anticancer Res., 11, 253 (1991).
65. G. K. Poochikian and J. C. Cradock, J. Pharm. Sci., 68, 728 (1979).
66. L. A. Darwish, A. T. Florence, and A. M. Saleh, J. Pharm. Sci., 78, 577 (1989).
67. C. Confalonieri, G. Cristina, and M. Farina, J. Pharm. Biomed. Anal., 9, 1 (1991).
68. K. P. Flora, J. C. Cradock, and G. K. Poochikian, J. Pharm. Pharmacol., 32, 577 (1980).
69. R. Kirsch, P. J. Bugelski, and G. Poste, Ann. NY Acad. Sci., 507, 141 (1987).
70. M. J. Ostro and P. R. Cullis, Am. J. Hosp. Pharm., 46, 1576 (1989).
71. G. Storm, H. P. Wilms, and D. J. A. Crommelin, Biotherapy, 3, 25 (1991).
72. N. J. Zuidam, S. S. L. Lee, and D. J. A. Crommelin, Pharm. Res., 10, 1591 (1993).
73. H. Talsma and D. J. A. Crommelin, BioPharm, October 1992, p. 36.
74. H. Talsma and D. J. A. Crommelin, BioPharm, November-December 1992, p. 38.
75. H. Talsma and D. J. A. Crommelin, Pharm. Technol. Int., January 1993, p. 36.
76. R. Perez-Soler, Cancer Treatment Res., 16, 67 (1989).
77. S. Amselem, A. A. Gabizon, and Y. Barenholz, J. Pharm. Sci., 79, 1045 (1990).
78. R. Perez-Soler and W. Priebe, Cancer Res., 50, 4260 (1990).
79. E. G. Mayhew, D. Lasic, S. Babbar, and F. J. Martin, Int. J. Cancer, 51, 302 (1992).
80. J. Duque, O. Yazan, L. J. A. Dubeau, E. A. Forssen, R. T. Proffitt, and Z. A. Tokes, Proc. Am. Assoc. Cancer Res., 34, 365 (1993).
81. R. Perez-Soler, Y. H. Ling, Y. Zou, and W. Priebe, Proc. Am. Assoc. Cancer Res., 34, 324 (1993).
82. A. A. Gabizon, R. Chisin, S. Amselem, S. Druckmann, R. Cohen, D. Goren, I. Fromer, T. Peretz, A. Sulkes, and Y. Barenholz, Br. J. Cancer, 64, 1125 (1991).
83. J. Treat, A. Greenspan, D. Forst, J. A. Sanchez, V. J. Ferrans, L. A. Potkul, P. V. Woolley, and A. Rahman, J. Natl. Cancer Inst., 82, 1706 (1990).
84. L. Bolesak, S. Younster, C. Swenson, S. Saletan, A. Elias, and R. Mazanet. Proc. Am. Assoc. Cancer Res., 34, 364 (1993).
85. B. A. Conley, M. J. Egorin, M. Y. Whitacre, D. C. Carter, E. G. Zuhowski, and D. A. Van Echo, Cancer Chemother Pharmacol., 33, 107 (1993).
86. R. Perez-Soler and A. R. Khokhar, Cancer Res., 52, 6341 (1992).
87. S. Sugarman and R. Perez-Soler, Proc. Am. Assoc. Cancer Res., 34, 422 (1993).
88. S. S. Daoud, M. I. Fetouh, and B. C. Giovanella, Proc. Am. Assoc. Cancer Res., 34, 367 (1993).
89. E. Hänseler, K. Rentsch, D. H. Horber, R. A. Schwendener, and C. Sauter, Proc. Am. Assoc. Cancer Res., 34, 364 (1993).
90. A. Sharma, E. Mayhew, and R. M. Straubinger, Cancer Res., 53, 5877 (1993).
91. A. Sharma and R. M. Straubinger, Pharm. Res., 11, 889 (1994).
92. M. Fresta, A. Villari, G. Puglisi, and G. Cavallaro, Int. J. Pharm., 99, 145 (1993).
93. B. Gause, D. L. Longo, J. Janik, J. Smith II, B. Curti, A. Ochoa, W. C. Kopp, P. Anderson, and W. J. Urba, Proc. Am. Soc. Clin. Oncol., 12, 293 (1993).
94. D. A. Bellnier, Y. Ho, R. K. Pandey, J. R. Missert, and T. J. Dougherty, Photochem. Photobiol., 50, 221 (1989).
95. S. A. Landaw, G. S. Drummond, and A. Kappas, Pediatrics, 84, 1091 (1989).
96. N. Udupa, K. S. Chandraprakash, P. Umadevi, and G. K. Pillai, Drug Dev. Ind. Pharm., 19, 1331 (1993).
97. S. J. Douglas, S. S. Davis, and L. Ilium, CRC Crit. Rev. Ther. Drug Carrier Syst., 3, 233 (1987).
98. P. Couvreur, L. Roblot-Treupel, M. F. Poupon, F. Brasseur, and F. Puisieux, Adv. Drug Delivery Rev., 5, 209 (1990).
99. P. Beck, J. Kreuter, R. Reszka, and I. Fichtner, J. Microencap., 10, 101 (1993).
100. H. Abe, Y. Doi, and Y. Yamamoto, Macromol. Rep., A29, 229 (1992).
101. B. Leyland-Jones, Semin. Oncol., 20, 12 (1993).
102. M. R. Violante, J. F. Lanzafame, and L. P. Medisperse, Proc. Am. Assoc. Cancer Res., 36, 309 (1995).
103. M. S. Sands, M. R. Violante, and G. Gadeholt, Invest. Radiol., 22, 408 (1987).
104. S. Wei, Y. Sun, J. Zhang, W. Tan, J. Xie, X. Li, and J. Zhu, J. Chin. Pharm. Sci., 1, 33 (1992).
105. J. H. Goedemoed, K. De Groot, A. M. E. Claessen, and R. J. Scheper, J. Controlled Release, 17, 235 (1991).
106. J. H. Goedemoed, E. H. G. Mense, K. De Groot, A. M. E. Claessen, and R. J. Scheper, J. Controlled Release, 17, 245 (1991).
107. Y. Mizushima, Y. Shoji, T. Kato, M. Fukushima, and S. Kurozumi, J. Pharm. Pharmacol., 38, 132 (1986).
108. R. Jeyanthi and K. Panduranga Rao, Int. J. Pharm., 35, 177 (1987).
109. R. Narayani and K. Pandurango Rao, Int. J. Pharm., 95, 85 (1993).
110. M. M. Ghorab, H. Zia, and L. A. Luzzi, J. Microencap., 7, 447 (1990).
111. S. S. Davis, C. Washington, P. West, L. Ilium, G. Liversidge, L. Sternson, and R. Kirsch, Ann. NY Acad. Sci., 709, 75 (1987).
112. P. K. Hansrani, S. S. Davis, and M. J. Groves, J. Parent. Sci. Technol., 4, 145 (1983).
113. L. C. Collins-Gold, R. T. Lyons, and L. C. Bartholow, Adv. Drug Delivery Rev., 5, 189 (1990).
114. R. J. Prankerd and V. J. Stella, J. Parenter. Sci. Technol., 44, 139 (1990).
115. O. Von Dardel, C. Mebius, T. Mossberg, and B. Svensson, Br. J. Anaesth., 55, 41 (1983).
116. T. L. Whateley, G. Steele, J. Urwin, and G. A. Smail, J. Clin. Hosp. Pharm., 9, 113 (1984).
117. B. L. McNiff, Am. J. Hosp. Pharm., 34, 1080 (1977).
118. K. E. Avis and B. E. Morris, in Pharmaceutical Dosage Forms: Parenteral Medications (K. E. Avis, L. Lachman, and H. A. Lieberman, eds.), Marcel Dekker, New York, 1984, p. 6.
119. G. D. Chanana and B. B. Sheth, J. Parenter. Sci. Technol., 47, 130 (1993).
120. I. L. Gordon, R. Kar, R. W. Opfell, and A. G. Wile, Cancer Res., 47, 5070 (1987).
121. M. M Ames, R. L. Richardson, J. S. Kovach, C. G. Moertel, and M. J. O'Connell, Cancer Res., 50, 206 (1990).
122. R. Paborji, C. Riley, and V. Stella, Int. J. Pharm., 42, 243 (1988).
123. R. Vishnuvajjala, E. Tabibi, D. Lednicer, and R. Varma, NCI Investigational Drugs - Pharmaceutical Data, 1994, p. 108.
124. J. A. Omotosho, T. L. Whateley, and A. T. Florence, J. Microencap., 6, 183 (1989).
125. K. Lee and K. Chan, Pharm. Sci. Commun., 4, 39 (1993).
126. M. K. Bijsterbosch and T. J. C. Van Berkel, Adv. Drug Delivery Rev., 5, 231 (1990).
127. J. M. Shaw, K. V. Shaw, S. Yanovich, M. Iwanik, W. S. Futch, A. Rosowsky, and L. B. Schook, Ann. NY Acad. Sci., 507, 252 (1987).
128. D. K. Spady and J. M. Dietschy, Proc. Natl. Acad. Sci. USA, 82, 4526 (1985).
129. M. Masquelier, S. Vitols, and C. Peterson, Cancer Res., 46, 3842 (1986).
130. P. C. De Smidt, LDL-mediated delivery of antineoplastic drugs, thesis, Leiden, The Netherlands (1991).
131. B. Lundberg, Cancer Chemother. Pharmacol., 29, 241 (1992).
132. S. Levastel-Delattre, F. Martin-Nizard, V. Clavey, P. Testard, G. Favre, G. Doualin, H. S. Houssaini, J. M. Bard, P. Duriez, C. Delbart, G. Soula, D. Lesieur, I. Lesieur, J. C. Cazin, M. Cazin, and J. C. Fruchart, Cancer Res., 52, 3629 (1992).
133. B. Lundberg, Cancer Res., 47, 4105 (1987).
134. S. Vallabhajosula, H. S. Gilbert, S. J. Goldsmith, M. Paii, M. M. Hanna, and H. N. Ginsberg, Ann. Intern. Med., 110, 208 (1989).
135. D. Filipowska, T. Filipowska, B. Morelowska, W. Kazanowska, T. Laudanski, S. Lapinjoki, M. Akerlund, and A. Breeze, Cancer Chemother. Pharmacol., 29, 396 (1992).
136. T. Kawaguchi, A. Tsugane, K. Higashide, H. Endoh, T. Hasegawa, H. Kanno, T. Seki, K. Juni, T. Fukushima, and M. Nakano, J. Pharm. Sci., 81, 508 (1992).
137. Z. Zhao, G. I. Kingston, and A. R. Crosswell, J. Natl. Proc., 54, 1607 (1991).
138. A. E. Matthew, M. R. Mejillano, J. P. Nath, R. H. Himes, and V. J. Stella, J. Med. Chem., 35, 145 (1992).
139. C. I. Hong, R. J. Bernacki, S. W. Hui, Y. Rustum, and C. R. West, Cancer Res., 50, 4401 (1990).
140. G. Giammona, B. Carlisi, G. Cavallaro, G. Pitarresi, and S. Palazzo, Eur. J. Pharm. Biopharm., 38, 159 (1992).
141. Y. Song, H. Onishi, and T. Nagai, Int. J. Pharm., 98, 121 (1993).
142. A. Riggin, D. Clodfelter, A. Maloney, E. Rickard, and E. Massey, Pharm. Res., 8, 1264 (1991).
143. M. L. Roy, M. J. Pikal, E. C. Rickard, and A. M. Maloney, Dev. Biol. Standard, 74, 323 (1991).
144. A. Kimoto, T. Konno, T. Kawaguchi, Y. Miyauchi, and H. Maeda, Cancer Res., 52, 1013 (1992).
145. K. A. Commack and G. D. J. Adams, Animal Cell Biotechnol., 2, 251 (1985).
146. N. A. Williams and G. P. Polli, J. Parent. Sci. Technol., 38, 48 (1984).
147. R. N. Chilamkurti, J. Parenter. Sci. Technol., 46, 124 (1992).
148. M. S. Hora, R. K. Rana, and W. S. Flint, Pharm. Res., 9, 33 (1992).
149. V. J. Stella, K. Umprayn, and W. N. Waugh, Int. J. Pharm., 43, 191 (1988).
150. P. V. Gogineni, P. A. Crooks, and R. B. Murty, J. Chrom. Biomed. Appl., 620, 83 (1993).
151. J. H. Beijnen, H. Lingeman, H. A. Van Munster, and W. J. M. Underberg, J. Pharm. Biomed. Anal., 4, 275 (1986).
152. C. W. Taylor, S. E. Salmon, W. G. Satterlee, A. B. Robertone, T. M. McCloskey, M. T. Holdsworth, P. M. Plezia, and D. S. Alberts, Invest. New Drugs, 8, S51 (1990).
153. L. A. Al-Razzak, A. E. Benedetti, W. N. Waugh, and V. J. Stella, Pharm. Res., 7, 452 (1990).
154. J. D. Jonkman-de Vries, H. Talsma, R. E. C. Henrar, J. J. Kettenes-van den Bosch, A. Bult, and J. H. Beijnen, Cancer Chemother. Pharmacol., 34, 416 (1994).
155. E. Bajetta, R. Buzzoni, S. Viviani, F. Villani, P. Piotti, G. Gasparini, and G. Bonadonna, Cancer Treatment Rep., 69, 965 (1985).
156. C. Chiang, D. Fessier, K. Freebem, R. Thirucote, and P. Tyle, J. Pharm. Sci. Technol., 48, 24 (1994).